Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo.
作者信息
Scandura Carmen, Morgia Giuseppe, Russo Giorgio Ivan
机构信息
Urology Section, University of Catania, Catania, Italy.
出版信息
Transl Androl Urol. 2020 Oct;9(5):2305-2307. doi: 10.21037/tau-20-876.
Abstract
摘要
相似文献
1
Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo.评论：米拉贝隆的安全性和有效性：对接受米拉贝隆、抗毒蕈碱药物或安慰剂的膀胱过度活动症患者的大型综合临床试验数据库的分析。
Transl Androl Urol. 2020 Oct;9(5):2305-2307. doi: 10.21037/tau-20-876.
2
Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo".关于“米拉贝隆的安全性和有效性：对接受米拉贝隆、抗毒蕈碱药物或安慰剂治疗的膀胱过度活动症患者大型综合临床试验数据库的分析”的编辑评论
Transl Androl Urol. 2020 Jun;9(3):1009-1012. doi: 10.21037/tau-2020-02.
3
Re: Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.关于：米拉贝隆的安全性和有效性：对接受米拉贝隆、抗毒蕈碱药物或安慰剂治疗的膀胱过度活动症患者的大型综合临床试验数据库的分析。
J Urol. 2020 Dec;204(6):1385-1386. doi: 10.1097/JU.0000000000001286. Epub 2020 Oct 14.
4
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.米拉贝隆的心血管安全性：膀胱过度活动症患者综合临床试验数据库分析
J Am Soc Hypertens. 2018 Nov;12(11):768-778.e1. doi: 10.1016/j.jash.2018.08.001. Epub 2018 Aug 10.
5
Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.医学治疗过度活跃膀胱的疗效和安全性比较：系统文献回顾和混合治疗比较。
Eur Urol. 2014 Apr;65(4):755-65. doi: 10.1016/j.eururo.2013.11.010. Epub 2013 Nov 18.
6
Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics.老年患者膀胱过度活动症的口服药物治疗：米拉贝隆作为抗毒蕈碱药物的潜在替代药物
Curr Med Res Opin. 2016;32(4):621-38. doi: 10.1185/03007995.2016.1149806. Epub 2016 Feb 17.
7
Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder.关于使用选择性β3肾上腺素能受体激动剂米拉贝隆治疗膀胱过度活动症的现有证据。
Actas Urol Esp. 2013 Nov-Dec;37(10):640-51. doi: 10.1016/j.acuro.2013.05.003. Epub 2013 Jul 12.
8
A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.一项回顾性研究，比较米拉贝隆与抗毒蕈碱药物治疗西班牙膀胱过度活动症的治疗持久性和依从性。
BMC Urol. 2018 Sep 4;18(1):76. doi: 10.1186/s12894-018-0390-z.
9
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.米拉贝隆对比抗胆碱能单药治疗或联合治疗用于治疗膀胱过度活动症的疗效和耐受性：一项系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):324-333. doi: 10.1016/j.eururo.2018.03.020. Epub 2018 Apr 23.
10
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.米拉贝隆治疗膀胱过度活动症：疗效、安全性及耐受性综述，重点关注男性、老年及抗毒蕈碱反应不佳人群以及亚洲膀胱过度活动症患者
Expert Rev Clin Pharmacol. 2017 Feb;10(2):131-151. doi: 10.1080/17512433.2017.1275570. Epub 2017 Jan 16.
本文引用的文献
1
Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.米拉贝隆的安全性和疗效：接受米拉贝隆、抗毒蕈碱药物或安慰剂的膀胱过度活动症患者大型综合临床试验数据库分析。
Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18.
2
Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome.米拉贝隆的心血管安全性：膀胱过度活动症患者综合临床试验数据库分析
J Am Soc Hypertens. 2018 Nov;12(11):768-778.e1. doi: 10.1016/j.jash.2018.08.001. Epub 2018 Aug 10.
3
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.米拉贝隆对比抗胆碱能单药治疗或联合治疗用于治疗膀胱过度活动症的疗效和耐受性：一项系统评价和网络荟萃分析。
Eur Urol. 2018 Sep;74(3):324-333. doi: 10.1016/j.eururo.2018.03.020. Epub 2018 Apr 23.
4
EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence.EAU 指南：尿失禁的评估和非手术治疗。
Eur Urol. 2018 Apr;73(4):596-609. doi: 10.1016/j.eururo.2017.12.031. Epub 2018 Feb 3.
5
Epidemiology and management of chronic constipation in elderly patients.老年患者慢性便秘的流行病学与管理
Clin Interv Aging. 2015 Jun 2;10:919-30. doi: 10.2147/CIA.S54304. eCollection 2015.
6
The role of mirabegron in overactive bladder: a systematic review and meta-analysis.米拉贝隆在膀胱过度活动症中的作用：一项系统评价和荟萃分析。
Urol Int. 2014;93(3):326-37. doi: 10.1159/000361079. Epub 2014 Aug 7.
7
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.米拉贝隆治疗膀胱过度活动症：疗效、安全性和耐受性评价。
Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. Epub 2013 Oct 11.
8
The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.米拉贝隆治疗 OAB 的疗效和安全性：III 期临床试验的系统评价和荟萃分析。
Int Urol Nephrol. 2014 Jan;46(1):275-84. doi: 10.1007/s11255-013-0509-9. Epub 2013 Jul 30.
9
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study.美国、英国和瑞典下尿路症状（LUTS）的患病率：下尿路症状流行病学（EpiLUTS）研究结果
BJU Int. 2009 Aug;104(3):352-60. doi: 10.1111/j.1464-410X.2009.08427.x. Epub 2009 Mar 5.
10
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.五个国家基于人群的尿失禁、膀胱过度活动症及其他下尿路症状调查：EPIC研究结果
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. Epub 2006 Oct 2.
Zotero 插件